Chemotherapy for advanced poorly differentiated pancreatic neuroendocrine carcinoma

Journal of Hepato-biliary-pancreatic Sciences
Masafumi IkedaTakuji Okusaka

Abstract

Pancreatic neuroendocrine carcinoma (P-NEC) resembles small cell lung carcinoma in its biologic and clinical features, such as rapid growth and relatively high sensitivity to platinum-based chemotherapy. And, etoposide plus cisplatin (EP) or irinotecan plus cisplatin (IP), recommended by guidelines for the treatment of small cell lung carcinoma, has also been widely used for the treatment of unresectable NEC. Both regimens have been demonstrated to show favorable efficacy and have been acknowledged as de facto standard regimens for unresectable NEC, although it remains unclear which of the two regimens might yield more favorable outcomes. Therefore, a phase III trial of EP vs. IP has been planned for unresectable gastrointestinal, hepatobiliary or pancreatic NEC by the Japan Clinical Oncology Group. For patients with unresectable NEC who are refractory or intolerant to these regimens, no standard regimens have been established. Everolimus, an mTOR inhibitor, is likely to be effective in such patients, as there have been sporadic reports of the usefulness of everolimus in the treatment of P-NEC. A multicenter phase II trial is underway to elucidate the efficacy and safety of everolimus in patients with P-NEC who are refractory o...Continue Reading

References

Jul 26, 2006·Digestive Diseases and Sciences·Matthew H KulkeCharles S Fuchs
Sep 13, 2006·Virchows Archiv : an International Journal of Pathology·G RindiUNKNOWN European Neuroendocrine Tumor Society (ENETS)
Feb 22, 2007·Neuroendocrinology·Ola NilssonUNKNOWN European Neuroendocrine Tumor Society
Oct 18, 2007·Neuroendocrinology·Hakan AhlmanUNKNOWN Frascati Consensus Conference participants
Jun 21, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·James C YaoDouglas B Evans
Aug 7, 2009·Cancer Chemotherapy and Pharmacology·Takashi ShidaMasaru Miyazaki
Feb 11, 2011·The New England Journal of Medicine·James C YaoUNKNOWN RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group
Feb 18, 2011·Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association·Natsuko Tsuda OkitaKuniaki Shirao
Sep 13, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·H SorbyeU Knigge
Jan 13, 2015·F1000prime Reports·Thomas E Stinchcombe

❮ Previous
Next ❯

Citations

Apr 1, 2016·Nature Reviews. Clinical Oncology·Xavier M KeutgenElectron Kebebew
Dec 12, 2018·Pancreas·Bhavina D O Batukbhai, Ana De Jesus-Acosta
Jan 19, 2019·Endocrine Reviews·Andrea Mafficini, Aldo Scarpa
Aug 20, 2016·Journal of Gastroenterology·Tetsuhide ItoMasayuki Imamura
Jun 17, 2020·Frontiers in Oncology·Martine BocchiniMassimiliano Mazza
Apr 30, 2017·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Susumu HijiokaNobumasa Mizuno

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carcinoma, Islet Cell (Keystone)

Islet Cell Carcinoma or Pancreatic Neuroendocrine Tumours arise in the hormone producing cells of the pancreas. These tumors can be either malignant or benign. Discover the latest research on islet cell carcinoma in this feed.

Carcinoma, Islet Cell

Islet Cell Carcinoma or Pancreatic Neuroendocrine Tumours arises in the hormone producing cells of the pancreas. These tumors can be either malignant or benign. Discover the latest research on Islet Cell Carcinoma here.

Adenoma, Islet Cell

Islet Cell Adenoma arises in the islet cells, which are insulin producing cells of the pancreas. These tumors can be either malignant or benign. Discover the latest research on Islet Cell Adenoma here.